What is Orexa?
Headquartered in Herpen, The Netherlands, Orexa operates at the intersection of pharmacology and patient-centric care. The company is currently advancing a robust pipeline of phase 2 clinical studies, targeting complex conditions such as Post-Operative Ileus, Anorexia Nervosa, and Cachexia. By leveraging a well-known anesthetic as the foundation for its lead compound, Orexa seeks to improve patient outcomes, reduce hospital recovery times, and drive systemic cost savings within the healthcare sector. Its strategic focus on therapeutic areas where increased food intake is clinically beneficial highlights a unique, evidence-based business model that prioritizes both efficacy and economic viability in modern medicine.
How much funding has Orexa raised?
Orexa has raised a total of $939K across 1 funding round:
Unspecified
$939K
Unspecified (2024): $939K, investors not publicly disclosed
Key Investors in Orexa
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Orexa?
With this major enterprise-level funding, Orexa is well-positioned to accelerate its ongoing phase 2 trials and prepare for subsequent regulatory milestones. The capital will likely be deployed to scale clinical operations, enhance research and development capabilities, and solidify the company's intellectual property portfolio. As the firm transitions from early-stage development to more advanced clinical phases, the focus will shift toward demonstrating long-term safety and efficacy profiles. Investors and stakeholders will be closely monitoring the progression of the Cachexia study and the broader commercialization strategy, as these developments will be pivotal in determining Orexa's trajectory toward becoming a leader in specialized metabolic therapeutics.
See full Orexa company page
